Volume 28, Number 9—September 2022
Research
Fulminant Transfusion-Associated Hepatitis E Virus Infection Despite Screening, England, 2016–2020
Heli Harvala
, Claire Reynolds, Su Brailsford, and Katy Davison
, Claire Reynolds, Su Brailsford, and Katy Davison
Table 2
Incidence of hepatitis E virus RNA positive samples and estimated risk for nondetection, with 7-day window period risk for apheresis and whole blood donors. England, March 2016–December 2020
| Donation type, year | Incidence, HEV RNA–positive samples/1 million donors | Risk per 1 million if window period 7 days (95% CI) |
|---|---|---|
| Apheresis | ||
| 2016 | 1,966.5 | 37.69 (24.15–56.07) |
| 2017 | 1,532.6 | 29.37 (17.94–45.36) |
| 2018 | 1,935.8 | 37.10 (23.77–55.20) |
| 2019 | 1,241.5 | 23.79 (13.32–39.24) |
| 2020 |
2,052.7 |
39.34 (25.21–58.53) |
| Whole blood | ||
| 2016 | 2,401.9 | 46.03 (39.45–53.40) |
| 2017 | 1,184.6 | 22.70 (20.03–25.63) |
| 2018 | 1,344.6 | 25.77 (23.14–28.61) |
| 2019 | 1,788.8 | 34.28 (31.21–37.58) |
| 2020 | 1,614.9 | 30.95 (27.91–34.23) |
Page created: July 14, 2022
Page updated: August 19, 2022
Page reviewed: August 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.